Abstract | AIM: METHODS: We enrolled 38 patients with type 2 DM (20 males and 18 females, 65.7±9.9 years old, HbA1c levels <8.4%), and all patients gave written informed consent. Sitagliptin (50 mg/day) was added to current antidiabetic treatments and increased to 100 mg/day to achieve low HbA1c levels (<7.4%). Glucose and lipoprotein metabolism profiles were analyzed at 0, 4, and 12 weeks after sitagliptin administration. RESULTS:
Sitagliptin significantly decreased fasting levels of triglyceride (TG) (161±90 vs. 130±66 mg/dl, p<0.01) and non-HDL-C (129±29 vs. 116±20 mg/dl, p<0.01) in combination with glucose (150±47 vs. 129±27 mg/dl, p<0.01) and HbA1c (7.1±0.6 vs. 6.6±0.7 mg/dl, p<0.001). Sitagliptin also significantly decreased the fasting levels of apolipoprotein ( apo) B-48 (7.8±6.7 vs. 5.6±4.0 µg/ml, p<0.01), remnant lipoprotein cholesterol (15.3±9.5 vs. 12.0±7.9 mg/dl, p<0.05) and other apolipoproteins, such as apoB, apoC-II, apoC-III, and apoE. Analyses of the lipoprotein profiles of fasting sera revealed that sitagliptin significantly decreased cholesterol and TG levels of lipoprotein fractions in the size of very low density lipoprotein and low density lipoprotein. CONCLUSIONS: These findings indicated that sitagliptin administration ameliorated the lipid and lipoprotein profiles in patients with diabetes, which may be due to the decrease in atherogenic remnant lipoproteins (UMIN#000013218).
|
Authors | Daisaku Masuda, Takuya Kobayashi, Masami Sairyou, Hiroyuki Hanada, Tohru Ohama, Masahiro Koseki, Makoto Nishida, Norikazu Maeda, Shinji Kihara, Tatsuya Minami, Koji Yanagi, Yasushi Sakata, Shizuya Yamashita |
Journal | Journal of atherosclerosis and thrombosis
(J Atheroscler Thromb)
Vol. 25
Issue 6
Pg. 512-520
(Jun 01 2018)
ISSN: 1880-3873 [Electronic] Japan |
PMID | 29199201
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers
- Dipeptidyl-Peptidase IV Inhibitors
- Lipoproteins
- Sitagliptin Phosphate
|
Topics |
- Aged
- Biomarkers
(metabolism)
- Diabetes Mellitus, Type 2
(complications)
- Dipeptidyl-Peptidase IV Inhibitors
(therapeutic use)
- Female
- Follow-Up Studies
- Humans
- Hyperglycemia
(etiology, metabolism, prevention & control)
- Hypoglycemia
(etiology, metabolism, prevention & control)
- Lipoproteins
(metabolism)
- Male
- Prognosis
- Prospective Studies
- Sitagliptin Phosphate
(therapeutic use)
|